Australia's TGA Warns Of Shortage Of Often-Vital Overactive Thyroid Drug
This article was originally published in PharmAsia News
Executive Summary
Australia's Therapeutic Goods Administration warned of a global shortage of U.S.-based Link HealthCare's Neo-Mercazole (carbimazole) drug for treating hyperthyroidism, to the point some patients face a life-threatening situation.